Related Experiment Videos
Limitations in randomised controlled trials evaluating drug effects in mania
1Mood Disorders Research Unit, Aarhus University Psychiatric Hospital, Risskov, Denmark. rl@psykiatri.aaa.dk
Abstract:
Considering the increasing number of drugs evaluated for mania in randomised controlled trials (RCTs) and the potential discrepancies between recommendations based on RCTs and the antimanic treatment given in clinical practice, this paper addresses some issues related to RCTs on drug effects in mania. One major question raised in the paper is to what extent selection prior to the point of randomisation in RCTs in mania may limit the applicability of study results to patients seen in ordinary clinical practice. Although such limitations in generalisability can be difficult to investigate empirically, it is emphasised that they should be openly discussed in the reports of RCTs. Another major focus is the issue of evaluation and interpretation of outcome, including a discussion of various response criteria based on mania rating scale scores. It is pointed out that essential criteria of dimensionality have only been sufficiently evaluated for the Bech-Rafaelsen Mania Rating Scale, although the fulfilment of such criteria are prerequisites for adding up the item scores to a total score reflecting the severity of mania. It is suggested that response defined as a decline in mania score below a certain limit may have some advantages over the commonly used 50% reduction criterion. The issues arising from the unusual high drop-out rates of around 50% are also addressed. Despite the fact that we need rigorous placebo-controlled trials to establish antimanic efficacy of new compounds, we also need large scale pragmatic studies using broad inclusion criteria, comparing the various treatments, alone or in combination, to investigate how they work in clinical practice. These studies maybe randomised but open and use simple but relevant outcome measures.
Insights
Randomized controlled trials (RCTs) for mania drugs may not reflect real-world practice due to patient selection. New response criteria and pragmatic studies are needed for better clinical applicability of antimanic treatments.
Area of Science:
- Psychiatry
- Clinical Pharmacology
Background:
- Increasing number of drugs evaluated for mania in randomized controlled trials (RCTs).
- Potential discrepancies exist between RCT recommendations and clinical practice for antimanic treatment.
- Concerns regarding the generalizability of RCT findings to patients in ordinary clinical practice.
Purpose of the Study:
- To address issues related to RCTs on drug effects in mania.
- To examine the impact of patient selection on the applicability of RCT results.
- To discuss the evaluation and interpretation of outcomes, including response criteria and drop-out rates.
Main Methods:
- Discussion of generalizability limitations in RCTs for mania.
- Analysis of various response criteria based on mania rating scale scores.
- Addressing high drop-out rates in mania drug trials.
Main Results:
- Generalizability of RCTs may be limited by pre-randomization selection criteria.
- The Bech-Rafaelsen Mania Rating Scale is sufficiently evaluated for dimensionality.
- A response defined by a score decline below a limit may offer advantages over the 50% reduction criterion.
- High drop-out rates (around 50%) are a significant issue in mania RCTs.
Conclusions:
- Open discussion of generalizability limitations is crucial in RCT reports.
- Rigorous placebo-controlled trials are necessary for efficacy, but pragmatic studies are needed for clinical practice insights.
- Large-scale pragmatic studies with broad inclusion criteria and relevant outcome measures are essential to understand treatment effectiveness in real-world settings.